Loading…

Medical Research Finder

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

Venetoclax + Rituximab & Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

In previous analyses of the MURANO study, ﬁxed-duration venetoclax plus rituximab (VenR) resulted in improved progression-free survival (PFS) compared with bendamustine + rituximab (BR) in patients with relapsed or refractory Chronic lymphocytic leukemia (CLL) / Small lymphocytic lymphoma.
Kater et al. 2020 JCO 38: 4042–4054

Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration
Hilal et al. 2020 JAMA Intern. Med. 180: 1108
Venetoclax Plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations From the MURANO Phase III Study
Kater et al. 2020 JCO 38: 4042–4054
Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia
Seymour et al. 2018 NEJM 378: 1107-1120

7/2/2026